Copyright © 1996 by the European Society of Cardiology.
© 1996 1996 The European Society of Cardiology
Follow-up of atrial fibrillation: The initial experience of the Canadian Registry of Atrial Fibrillation
* St Paul's Hospital Vancouver
Hamilton General Hospital Hamilton
Ottawa Civic Hospital Ottawa
University of Western Ontario London
|| University of Calgary Calgary
¶ Montréal Heart Institute Montréal, Canada
Correspondence: Dr Charles R. Kerr, Room 247, St Paul's Hospital, 108 Burrard Street, Vancouver, B.C., Canada, V6Z 1Y6
Previous reports of the follow-up of patients with atrial fibrillation have been confusing because of the variety of clinical presentations, heterogeneity of underlying pathology, and the initiation of follow-up at various stages of the patient's disease. The Canadian Registry of Atrial Fibrillation (CARAF) is a non-interventional, follow-up study of patients enrolled at the time of their initial diagnosis with atrial fibrillation at seven Canadian centres. At baseline, a comprehensive database recorded clinical, laboratory, and echocardiographic variables. No specific intervention was initiated and care was left to the attending physicians. Follow-up was performed at 3 months, 1 year, then annually. Echocardiograms were repeated every 2 years. Recurrence of atrial fibrillation, medical intervention, stroke, death, and other significant events have been specifically recorded. To date, 967 patients have been enrolled. Seven hundred and sixty-seven patients have been followed for 1 year, 468 for 2 years, and 217 for 3 years.
Several studies have been undertaken on these patients. One study compared the variables of patients who were symptomatic with those who were asymptomatic. This study demonstrated that symptoms were more likely to occur if the patient were younger, had high blood pressure and high ventricular response during atrial fibrillation, and were female. These all achieve statistical significance and a formula was developed to predict the probability of symptoms in different subgroups of patients.
Antiarrhythmic drug use was evaluated. Sotalol and propafenone were the most commonly used drugs and their use increased when atrial fibrillation was recurrent. Many patients initially received no antiarrhythmic drugs. Trends suggest that therapy is more aggressive with recurrence of the arrhythmia.
The prevalence of thyroid abnormalities was investigated utilizing sensitive TSH measurements. This showed that overt hyperthyroidism is rare (1%) but laboratory abnormalities and history of thyroid dysfunction occurred more frequently, in 19% of patients.
Another study evaluated antithrombotic therapy. Factors known to increase stroke risk, including congestive heart failure, previous stroke, and large left atrium all increased the use of anticoagulants. Anticoagulants were used more frequently in patients over the age of 65 and in patients with recurrent or chronic atrial fibrillation. There was concern that hypertension, shown to be a high predictor of stroke, did not result in a significant use of warfarin. Aspirin use was common in patients not placed on anticoagulants.
Further studies are being undertaken with the ultimate goal to utilize baseline data to predict clinical outcomes.
Key Words: Atrial fibrillation • thyroid function • antiarrhythmic drugs
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  X. Du, T. Ninomiya, B. de Galan, E. Abadir, J. Chalmers, A. Pillai, M. Woodward, M. Cooper, S. Harrap, P. Hamet, et al. Risks of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation: results of the ADVANCE study Eur. Heart J., May 1, 2009; 30(9): 1128 - 1135. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Kaireviciute, A. Aidietis, and G. Y.H. Lip Atrial fibrillation following cardiac surgery: clinical features and preventative strategies Eur. Heart J., February 2, 2009; 30(4): 410 - 425. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. L. Page Newly Diagnosed Atrial Fibrillation N. Engl. J. Med., December 2, 2004; 351(23): 2408 - 2416. [Full Text] [PDF]
|
|
|
|
 |
|
 Endorsed by the Mediterranean Society of Pacing an, WRITING COMMITTEE MEMBERS, R. L. McNamara, L. M. Brass, J. P. Drozda Jr, A. S. Go, J. L. Halperin, C. R. Kerr, S. Levy, D. J. Malenka, et al. ACC/AHA Key Data Elements and Definitions for Measuring the Clinical Management and Outcomes of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Data Standards on Atrial Fibrillation) Circulation, June 29, 2004; 109(25): 3223 - 3243. [Full Text] [PDF]
|
|
|
|
|
|
R. L. Page, T. W. Tilsch, S. J. Connolly, D. J. Schnell, S. R. Marcello, W. E. Wilkinson, E. L.C. Pritchett, and for the Azimilide Supraventricular Arrhythmia Prog Asymptomatic or "Silent" Atrial Fibrillation: Frequency in Untreated Patients and Patients Receiving Azimilide Circulation, March 4, 2003; 107(8): 1141 - 1145. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. S. Go, E. M. Hylek, L. H. Borowsky, K. A. Phillips, J. V. Selby, and D. E. Singer Warfarin Use among Ambulatory Patients with Nonvalvular Atrial Fibrillation: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study Ann Intern Med, December 21, 1999; 131(12): 927 - 934. [Abstract] [Full Text] [PDF]
|
|